Page 68 - ARNM-2-3

Advances in Radiotherapy
& Nuclear Medicine NCRT for T3N0M0 ESCC

Appendix

Table A1. Univariate and multivariate Cox regression analyses for the overall survival of the entire cohort after PSM
Variables Univariate Multivariate
HR (95% CI) P‑value HR (95% CI) P‑value
Age (years) >65 versus≤65 1.91 (1.18 – 3.07) 0.009 1.89 (1.17 – 3.06) 0.009
Sex: Female versus Male 1.12 (0.60 – 2.08) 0.729
KPS: 80 versus≥90 1.31 (0.67 – 2.57) 0.450
Weight loss: No versus Yes 0.85 (0.51 – 1.41) 0.524
Tumor location 0.545
Upper 1.00 (reference)
Middle 0.75 (0.39 – 1.43)
Lower 0.70 (0.38 – 1.30)
Tumor length (cm): >5 versus≤5 2.10 (0.66 – 6.70) 0.261
LVI: No versus Yes 0.86 (0.12 – 6.25) 0.886
PNI: No versus Yes 0.98 (0.49 – 1.98) 0.958
Total lymph nodes excised: ≥18 versus<18 0.49 (0.30 – 0.82) 0.005 0.47 (0.28 – 0.79) 0.004
Group: NCRT+S versus surgery 0.59 (0.36 – 0.98) 0.039 0.57 (0.34 – 0.94) 0.028
Note: P<0.05 indicates statistically significant differences.
Abbreviations: CI: Confidence intervals; HR: Hazard ratio; KPS: Karnofsky Performance Status; LVI: Lymphovascular invasion; NCRT+S: Neoadjuvant
chemoradiotherapy plus surgery; PNI: Perineural invasion.

Volume 2 Issue 3 (2024) 13 doi: 10.36922/arnm.3821